AbbVie Inc.

• ABBV Stock Price 24h change: +0.91%. From 216.15 USD to 218.11 USD. The price rose as investors reacted to positive Phase 3 trial results for its cancer drug and a major manufacturing facility acquisition.
• From a technical perspective, the stock is showing a "short-term recovery within a long-term consolidation": ABBV's 5-day and 20-day moving averages (approx. 218.01 and 215.79) indicate immediate bullish momentum, while the 14-day RSI at 56.32 suggests it is approaching overbought territory but still has room to run. Major resistance is seen near 223.77 (200-day MA), with support holding steady at 214.76.
• AbbVie reported positive Phase 3 results for Epcoritamab on January 16, showing significantly improved progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
• AbbVie announced on January 12 an exclusive licensing agreement with RemeGen to develop RC148, a novel bispecific antibody for advanced solid tumors, and confirmed the acquisition of an Arizona manufacturing facility to bolster its U.S. supply chain.
• The U.S. healthcare sector is adjusting to new executive orders focused on drug pricing and Medicaid reform, with AbbVie recently reaching a $100 billion investment agreement with the administration to improve drug access and affordability.
• Pharmaceutical stocks saw increased volatility as the industry faces shifting regulations on federal subsidies for health insurance marketplaces, potentially impacting patient enrollment and drug demand through 2026.

• ABBV Stock Price 24h change: +1.10%. From 216.15 USD to 218.53 USD. The rise is attributed to positive investor sentiment following the company's entry into the high-growth obesity market and strong guidance for its core immunology products, Skyrizi and Rinvoq.
• From a technical perspective, the stock is showing a mixed outlook: it is currently trading below its 50-day moving average ($226.15) but remains above the 200-day moving average ($216.99), indicating long-term support despite short-term bearish pressure. The 14-day RSI is approximately 38.80, suggesting the stock is approaching oversold territory and may be due for a technical rebound.
• AbbVie announced on January 15 that it completed the first human trial for GUB014295, a long-acting amylin analog for obesity, positioning the company in a high-growth pharmaceutical category.
• On January 16, AbbVie reported topline Phase 3 results for epcoritamab in relapsed/refractory DLBCL; while it improved progression-free survival, it did not show a statistically significant improvement in overall survival.
• On January 12, AbbVie reached a significant voluntary agreement with the federal administration to improve drug affordability, securing a three-year exemption from new tariffs and drug-pricing mandates in exchange for a $100 billion U.S. investment commitment.
• The U.S. officially completed its withdrawal from the World Health Organization on January 22, 2026, marking a major shift in international healthcare policy and regulatory coordination.
• Johnson & Johnson reported robust growth in its oncology sector on January 21, with sales for the multiple myeloma treatment Darzalex jumping 26.6%, signaling strong demand across the broader pharmaceutical industry.